Novel Mouse Models to define Genetic Drivers of Aggressive Prostate Cancer

定义侵袭性前列腺癌遗传驱动因素的新型小鼠模型

基本信息

  • 批准号:
    9461668
  • 负责人:
  • 金额:
    $ 17.13万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-04-15 至 2019-03-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): A fundamental gap in knowledge in prostate cancer (PCa) is how to distinguish indolent from aggressive disease. Further, genetic events that switch an indolent PCa to an aggressive phenotype are not well understood. Our proposed investigations will utilize two state-of-the-art genetically engineered mouse models (GEMMs) of PCa generated by the PI to address these gaps in knowledge. Expression of the Myc oncogene exclusive to mouse prostate epithelium results in indolent organ confined PCa. We have combined the Myc transgenic mouse model with additional models to establish novel GEMMs of PCa to perform a gene candidate and gene discovery approach to delineate genetic drivers of aggressive PCa progression. Specifically, aim 1 will determine if the retinoblastoma protein (Rb) is a suppressor of PCa metastasis. Specific aim 2 will utilize a sleeping beauty mutagenesis screen to identify novel candidate genetic drivers of PCa metastasis. Ultimately, these novel and state-of-the-art mouse models allow for prostate specific molecular events to be investigated. Our principle objective is to characterize our GEMMs to discover genetic switches which drive aggressive PCa. Overall, our proposed studies will significantly impact PCa research and how patients are clinically assessed to determine stratification of indolent from aggressive disease. In addition, through completing these studies, we will continue to achieve our longer term goals which are to identify and validate new therapeutic pathways/targets that may ultimately be used to treat patients with advanced PCa, and serum available biomarkers of PCa that identify aggressive PCa phenotypes.
 描述(由申请人提供):前列腺癌(PCA)知识的一个基本空白是如何区分惰性和侵袭性疾病。此外,将惰性前列腺癌转变为攻击性表型的遗传事件还没有被很好地理解。我们建议的研究将利用PI产生的两个最先进的PCa基因工程小鼠模型(GEMM)来解决这些知识差距。Myc癌基因在小鼠前列腺上皮细胞中的表达导致惰性器官受限的前列腺癌。我们将Myc转基因小鼠模型与其他模型相结合,建立了新的前列腺癌GEMM,以执行基因候选和基因发现的方法来描述侵袭性前列腺癌进展的遗传驱动因素。具体地说,Aim 1将确定视网膜母细胞瘤蛋白(Rb)是否是PCa转移的抑制因子。特定目的2将利用睡美人突变筛选来确定新的前列腺癌转移候选遗传驱动因素。最终,这些新颖和最先进的小鼠模型允许研究前列腺特异性分子事件。我们的主要目标是描述我们的GEMM,以发现驱动侵袭性PCA的遗传开关。总体而言,我们建议的研究将显著影响PCA研究以及如何对患者进行临床评估,以确定惰性疾病与侵袭性疾病的分层。此外,通过完成这些研究,我们将继续实现我们的长期目标,即确定和验证最终可能用于治疗晚期PCa患者的新的治疗途径/目标,以及识别侵袭性PCa表型的可用的PCa生物标志物。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate Cancer.
  • DOI:
    10.1158/1940-6207.capr-20-0186
  • 发表时间:
    2020-12
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Burkhart DL;Morel KL;Wadosky KM;Labbé DP;Galbo PM;Dalimov Z;Xu B;Loda M;Ellis L
  • 通讯作者:
    Ellis L
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Leigh Ellis其他文献

Leigh Ellis的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Leigh Ellis', 18)}}的其他基金

Identifying EZH2-dependent vulnerabilities in RB deficient prostate cancer
鉴定 RB 缺陷型前列腺癌中 EZH2 依赖性脆弱性
  • 批准号:
    10410374
  • 财政年份:
    2021
  • 资助金额:
    $ 17.13万
  • 项目类别:
Identifying EZH2-dependent vulnerabilities in RB deficient prostate cancer
鉴定 RB 缺陷型前列腺癌中 EZH2 依赖性脆弱性
  • 批准号:
    10154294
  • 财政年份:
    2021
  • 资助金额:
    $ 17.13万
  • 项目类别:
ATR Dependency as a Novel Therapeutic Target in Lethal RB Deficient Prostate Cancer.
ATR 依赖性作为致命性 RB 缺陷前列腺癌的新治疗靶点。
  • 批准号:
    10034539
  • 财政年份:
    2020
  • 资助金额:
    $ 17.13万
  • 项目类别:
ATR Dependency as a Novel Therapeutic Target in Lethal RB Deficient ProstateCancer
ATR 依赖性作为致命性 RB 缺陷前列腺癌的新治疗靶点
  • 批准号:
    10304098
  • 财政年份:
    2020
  • 资助金额:
    $ 17.13万
  • 项目类别:
ATR Dependency as a Novel Therapeutic Target in Lethal RB Deficient ProstateCancer
ATR 依赖性作为致命性 RB 缺陷前列腺癌的新治疗靶点
  • 批准号:
    10186723
  • 财政年份:
    2020
  • 资助金额:
    $ 17.13万
  • 项目类别:
ATR Dependency as a Novel Therapeutic Target in Lethal RB Deficient ProstateCancer
ATR 依赖性作为致命性 RB 缺陷前列腺癌的新治疗靶点
  • 批准号:
    10472549
  • 财政年份:
    2020
  • 资助金额:
    $ 17.13万
  • 项目类别:
Exploiting RB1 deficiency for the treatment of lethal neuroendocrine prostate cancer
利用 RB1 缺陷治疗致命性神经内分泌前列腺癌
  • 批准号:
    9763338
  • 财政年份:
    2016
  • 资助金额:
    $ 17.13万
  • 项目类别:
Exploiting RB1 deficiency for the treatment of lethal neuroendocrine prostate cancer
利用 RB1 缺陷治疗致命性神经内分泌前列腺癌
  • 批准号:
    9338195
  • 财政年份:
    2016
  • 资助金额:
    $ 17.13万
  • 项目类别:
Exploiting RB1 deficiency for the treatment of lethal neuroendocrine prostate cancer
利用 RB1 缺陷治疗致命性神经内分泌前列腺癌
  • 批准号:
    9152986
  • 财政年份:
    2016
  • 资助金额:
    $ 17.13万
  • 项目类别:

相似国自然基金

大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
  • 批准号:
    30840003
  • 批准年份:
    2008
  • 资助金额:
    12.0 万元
  • 项目类别:
    专项基金项目

相似海外基金

Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
  • 批准号:
    478914
  • 财政年份:
    2023
  • 资助金额:
    $ 17.13万
  • 项目类别:
    Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
  • 批准号:
    23K14913
  • 财政年份:
    2023
  • 资助金额:
    $ 17.13万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
  • 批准号:
    23K15035
  • 财政年份:
    2023
  • 资助金额:
    $ 17.13万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
  • 批准号:
    10657069
  • 财政年份:
    2023
  • 资助金额:
    $ 17.13万
  • 项目类别:
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
  • 批准号:
    10442874
  • 财政年份:
    2023
  • 资助金额:
    $ 17.13万
  • 项目类别:
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
  • 批准号:
    23H02698
  • 财政年份:
    2023
  • 资助金额:
    $ 17.13万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
  • 批准号:
    23K08326
  • 财政年份:
    2023
  • 资助金额:
    $ 17.13万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
  • 批准号:
    23K14614
  • 财政年份:
    2023
  • 资助金额:
    $ 17.13万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
  • 批准号:
    23K15075
  • 财政年份:
    2023
  • 资助金额:
    $ 17.13万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
  • 批准号:
    10743611
  • 财政年份:
    2023
  • 资助金额:
    $ 17.13万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了